IGA NEPHROPATHY (IGAN)

This early-phase study tests a new treatment using specially engineered immune cells (CD19 CAR-γδ T cells) for people with severe autoimmune kidney diseases like lupus nephritis, IgA nephropathy, and membranous nephropathy that haven't responded to standard therapies. About 15 pa…

This study tests an experimental drug called SLN12140 in 48 adults with IgA nephropathy, a kidney disease that is not well controlled by current treatments. Participants will receive either the drug or a placebo by injection for 36 weeks, with an optional open-label extension. Th…

This study tests whether Shenqi Yishen Granules, a traditional Chinese medicine, can lower protein levels in the urine of adults with IgA nephropathy, a kidney disease. About 102 participants will receive either the granules or a placebo to compare effects. The goal is to see if …

This early-phase study tests an experimental cell therapy called GT719 in about 30 adults with immune-mediated kidney diseases, such as IgA nephropathy and membranous nephropathy. The treatment uses specially designed cells to target and control the immune system's attack on the …

This study will follow 50 adults with IgA nephropathy who are taking sparsentan. Researchers want to see how the drug affects protein in the urine (albuminuria), a key sign of kidney damage. The study is observational, meaning it just watches what happens in real-world use, witho…

This study tests whether taking Nefecon for 15 months can prevent proteinuria (protein in urine) from returning in people with IgA nephropathy who have already responded to treatment. About 288 adults who have completed 9 months of Nefecon and have low protein levels will be rand…

This early-stage study tests a new drug called RG002C0106 in 24 adults to see how kidney problems affect the drug's safety and how the body processes it. Half the participants have normal kidneys, and half have mild-to-moderate kidney issues. The goal is to measure drug levels an…